Drug intelligence / Profile preview

JNJ-49122944

Development stage: Phase 1
Lead developer: Janssen Research & Development
Modality: Small Molecules
Administration: Intravenous

Overview

JNJ-49122944 is an investigational small molecule drug developed by Janssen Research & Development, a subsidiary of Johnson & Johnson. The compound was evaluated in a Phase 1 clinical trial to assess its safety, tolerability, and pharmacokinetics following a single intravenous dose in healthy male volunteers. As of the latest available information, the specific mechanism of action and therapeutic target for JNJ-49122944 remain undisclosed. No active indications or disease targets have been publicly reported, and there are no known brand names or alternative designations beyond its code name[1][2][3][4].

Beyond the preview

Go deeper on JNJ-49122944.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-49122944.

Explore the full profile